These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 6398221)

  • 1. Monoclonal antibodies: the possibilities for cancer therapy.
    Poynton CH; Reading CL
    Exp Biol; 1984; 43(1):13-33. PubMed ID: 6398221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
    Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC
    Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of small cell lung cancer cells in vitro from human bone marrow by a monoclonal antibody.
    Okabe T; Kaizu T; Ozawa K; Urabe A; Takaku F
    Cancer Res; 1985 May; 45(5):1930-3. PubMed ID: 2985239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monoclonal antibodies: therapeutic possibilities and limitations].
    Tax WJ; Capel PJ; Koene RA
    Tijdschr Kindergeneeskd; 1987 Feb; 55(1):1-9. PubMed ID: 3551184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.
    Iannello A; Ahmad A
    Cancer Metastasis Rev; 2005 Dec; 24(4):487-99. PubMed ID: 16408158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Present potential of immunotoxins.
    Poncelet P; Blythman HE; Carriere D; Casellas P; Dussossoy D; Gros O; Gros P; Jansen FK; Laurent JC; Liance MC
    Behring Inst Mitt; 1984 May; (74):94-100. PubMed ID: 6383330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement.
    Bast RC; Ritz J; Lipton JM; Feeney M; Sallan SE; Nathan DG; Schlossman SF
    Cancer Res; 1983 Mar; 43(3):1389-94. PubMed ID: 6337707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of neuroblastoma monoclonal antibodies for potential utilization in diagnosis and therapy.
    Cheung NK; Saarinen U; Neely J; Miraldi F; Strandjord S; Warkentin P; Coccia P
    Prog Clin Biol Res; 1985; 175():501-5. PubMed ID: 3991743
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro treatment of human acute lymphocytic leukemia cells in bone marrow with a cocktail of monoclonal antibodies.
    Nakamura H; Hirayama F; Tatsumi Y; Tani Y; Kubota Y; Kanakura Y; Oguma S; Ueda T; Shibata H; Masaoka T
    Jpn J Clin Oncol; 1984 Dec; 14 Suppl 1():537-42. PubMed ID: 6596454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomagnetic removal of L1210V leukemic cells from mouse bone marrow ex vivo.
    Wiedłocha A; Paprocka M; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1991; 39(3):235-41. PubMed ID: 1810216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
    Helfand SC; Hank JA; Gan J; Sondel PM
    Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.
    Strome SE; Sausville EA; Mann D
    Oncologist; 2007 Sep; 12(9):1084-95. PubMed ID: 17914078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
    Kinouchi T; Bander NH; Kotake T
    J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple reactivities of cytotoxic monoclonal antibodies against pancreatic islet cells.
    Suzuki M; Sharma B; Waldeck N; Charles MA
    Diabetes Res; 1984 Nov; 1(4):179-81. PubMed ID: 6397292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.
    Pimm MV
    Crit Rev Ther Drug Carrier Syst; 1988; 5(3):189-227. PubMed ID: 3060267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current possibilities in immunotherapy of cancer].
    von Fliedner V
    Schweiz Med Wochenschr; 1987 Feb; 117(7):243-8. PubMed ID: 3551061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-T cell monoclonal antibodies conjugated to ricin as potential reagents for human GVHD prophylaxis: effect on the generation of cytotoxic T cells in both peripheral blood and bone marrow.
    Quinones RR; Youle RJ; Kersey JH; Zanjani ED; Azemove SM; Soderling CC; Lebien TW; Beverley PC; Neville DM; Vallera DA
    J Immunol; 1984 Feb; 132(2):678-83. PubMed ID: 6606676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives of monoclonal antibodies in the acute leukaemias.
    Hervé P; Wijdenes J; Racadot E
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():198-201. PubMed ID: 2653503
    [No Abstract]   [Full Text] [Related]  

  • 20. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
    Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.